Retroviral bicistronic vectors
- PMID: 19180265
- DOI: 10.1358/dnp.2008.21.9.1290817
Retroviral bicistronic vectors
Abstract
The co-expression of genes can greatly enhance the efficiency and versatility of gene therapy applications. A variety of options exists to simultaneously express two genes in genetically modified cells. The most common approach relies on bicistronic vectors in which the genes are linked to each other by an internal ribosome entry site allowing co-translational expression of both cistrons. This review gives an overview of gene vector systems currently in use for coordinated expression of transgenes with particular focus on retroviral bicistronic vectors. The structural and functional characteristics of bicistronic vectors are discussed as well as factors influencing their efficiency such as the nature of the transgenes and the cell types in which they are expressed. Finally, the potential for clinical applications of retroviral bicistronic vectors in molecular genetics is highlighted.
Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
-
Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout.J Gene Med. 2000 Jul-Aug;2(4):243-9. doi: 10.1002/1521-2254(200007/08)2:4<243::AID-JGM115>3.0.CO;2-Q. J Gene Med. 2000. PMID: 10953915
-
Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.J Gene Med. 2005 Mar;7(3):276-87. doi: 10.1002/jgm.663. J Gene Med. 2005. PMID: 15515136
-
Improved gene expression by a modified bicistronic retroviral vector.Biochem Biophys Res Commun. 1995 Sep 25;214(3):910-7. doi: 10.1006/bbrc.1995.2373. Biochem Biophys Res Commun. 1995. PMID: 7575563
-
Design of retroviral vectors and helper cells for gene therapy.Pharmacol Rev. 2000 Dec;52(4):493-511. Pharmacol Rev. 2000. PMID: 11121508 Review.
-
Somatic transgenesis using retroviral vectors in the chicken embryo.Dev Dyn. 2004 Mar;229(3):630-42. doi: 10.1002/dvdy.10484. Dev Dyn. 2004. PMID: 14991718 Review.
Cited by
-
Construction of recombinant adenovirus containing picorna-viral 2A-peptide sequence for the co-expression of neuro-protective growth factors in human umbilical cord blood cells.Spinal Cord. 2016 Jun;54(6):423-30. doi: 10.1038/sc.2015.162. Epub 2015 Oct 6. Spinal Cord. 2016. PMID: 26439843
-
Protein coexpression using FMDV 2A: effect of "linker" residues.Biomed Res Int. 2013;2013:291730. doi: 10.1155/2013/291730. Epub 2013 Jun 12. Biomed Res Int. 2013. PMID: 23878801 Free PMC article.
-
Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications.BMC Biotechnol. 2013 Aug 22;13:67. doi: 10.1186/1472-6750-13-67. BMC Biotechnol. 2013. PMID: 23968294 Free PMC article.
-
Insert sequence length determines transfection efficiency and gene expression levels in bicistronic mammalian expression vectors.Int J Biochem Mol Biol. 2013 Dec 15;4(4):201-8. eCollection 2013. Int J Biochem Mol Biol. 2013. PMID: 24380024 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical